Peptide therapy TikTok claims: what the evidence actually supports

What did @.dreamingdiana actually say?

She used something called RETA for one month and GHK-Cu for about three weeks, primarily to address lower belly fat and inflammation associated with PCOS. She lost "less than 10 pounds," noticed some reduction in lower abdominal fat, and saw improvement in acne she attributes to GHK-Cu. She also flagged a real problem she ran into: eating one meal a day while on RETA led to muscle loss rather than fat loss. She stopped RETA after a month due to symptoms she doesn't fully describe. Her framing is relatively grounded, calling it "a tool" rather than a miracle, and she mentions the need to work out and eat properly. She does recommend it specifically for people with PCOS and pre-diabetes, while noting they should check with a doctor.

Does the science back this up?

Partially, but with some significant gaps. "RETA" appears to refer to retatrutide, a triple GIP/GLP-1/glucagon receptor agonist. It is not FDA-approved as of early 2025. GHK-Cu is a copper peptide with a more established research base, though mostly preclinical. Here is where each claim lands.

On retatrutide: a Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) showed 17.5% body weight reduction at 48 weeks with the highest dose tested. That is meaningful data, but it is from a controlled trial, not a compounded peptide used for one month. The fat distribution effects she describes, specifically visceral fat reduction, are plausible given the mechanism, but one month is a very short window for that outcome to fully materialize.

On GHK-Cu and acne: the evidence here is weaker. Pickart and Margolina (2018, Cosmetics) reviewed GHK-Cu's anti-inflammatory and tissue-remodeling properties in skin, but controlled trials specifically for acne are limited. Preclinical data is promising. Calling this a three-week acne result is plausible but not well-supported by clinical trials.

On PCOS and visceral fat: GLP-1 receptor agonists as a class have shown benefit for PCOS-related metabolic dysfunction. A meta-analysis by Tang et al. (2022, Reproductive BioMedicine Online) found GLP-1 agonists reduced BMI and fasting insulin in PCOS patients. Retatrutide's triple-receptor activity theoretically extends this benefit, but PCOS-specific data for retatrutide specifically does not exist yet.

What did they get wrong (or right)?

She got the muscle-loss concern right. Eating one meal a day while using a potent appetite suppressant is a real problem. GLP-1-based drugs cause weight loss through caloric restriction, and without adequate protein intake and resistance training, lean mass loss is a documented side effect. A study by Wilding et al. (2021, NEJM) on semaglutide noted that roughly 40% of weight lost included lean mass. She figured this out empirically, which is actually a useful data point for her audience.

What she got wrong, or at least incomplete: she recommends RETA for people with PCOS and pre-diabetes without any meaningful discussion of the risks. Retatrutide is not approved, has not been studied in PCOS populations specifically, and the compounded versions circulating through peptide channels are not equivalent to the drug tested in trials. Pancreatitis risk, thyroid C-cell concerns (seen across the GLP-1 class), and gastrointestinal side effects deserve mention. The "symptoms" she references but never names is a gap that matters when you are recommending something to 9,700 people.

Her instinct to stop after one month because her body was giving her signals is reasonable. Her framing of the result as modest and partial is also honest. Credit where it is due: she did not overclaim dramatic transformation.

What should you actually know?

Retatrutide is a triple agonist that showed strong clinical results in Phase 2 trials, but it is not approved and the compounded peptide versions sold online are not the same compound that was studied. There is no regulatory pathway confirming purity, dosing accuracy, or safety of those products. If you have PCOS and are interested in GLP-1-class medications, there are approved options, semaglutide and tirzepatide, with actual prescribing data and safety monitoring attached to them.

GHK-Cu has a reasonable evidence base for skin-related applications, primarily anti-inflammatory and collagen-stimulating effects, but "three weeks and my acne improved" is anecdote, not clinical evidence. It could be the peptide. It could be dietary changes from appetite suppression. It could be reduced inflammation from weight loss itself. You cannot isolate the variable here.

The OMAD (one meal a day) approach while using appetite-suppressing peptides is a pattern that keeps appearing in peptide content, and it is worth flagging plainly: inadequate caloric and protein intake during pharmacologically-driven weight loss accelerates lean mass loss. This is not a minor inconvenience. Muscle loss has long-term metabolic consequences, particularly for insulin sensitivity, which is already compromised in PCOS.

Anyone considering retatrutide specifically should know: no Phase 3 data exists, no long-term safety profile exists, and the PCOS indication she is recommending it for has not been studied in a controlled setting for this compound.